Neuland Labs Q4FY26 Income ₹788.7 Crore, EBITDA ₹319.4 Crore
Neuland Laboratories reported Q4FY26 Total Income of ₹788.7 crore, up 134.9% YoY. EBITDA was ₹319.4 crore, a 448.6% increase. PAT rose 666.3% to ₹212.5 crore. CEO Saharsh Davuluri expressed satisfaction with the strong finish to FY26, highlighting business visibility and strategic investments.
The substantial year-on-year growth in key financial metrics like revenue and profit, coupled with positive management commentary on future visibility, is expected to have a significant positive impact on investor sentiment and the company's stock.
The company reported significant year-on-year growth in Total Income, EBITDA, and Profit After Tax, along with positive commentary from the CEO regarding business performance and future outlook.
Neuland Laboratories Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a Total Income of ₹788.7 crore for Q4FY26, a significant increase of 134.9% compared to ₹335.8 crore in Q4FY25. EBITDA for the quarter stood at ₹319.4 crore, marking a 448.6% year-on-year growth from ₹58.2 crore in Q4FY25. The EBITDA margin improved to 40.5% from 17.3% in the same period last year. Profit Before Tax (PBT) surged by 636.6% to ₹287.0 crore from ₹39.0 crore, with a PBT margin of 36.4% compared to 11.6% YoY. Profit After Tax (PAT) also saw a substantial increase of 666.3%, reaching ₹212.5 crore in Q4FY26, up from ₹27.7 crore in Q4FY25.
Commenting on the performance, Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, stated, “We are pleased with the fact that we have ended FY26 on a strong note in line with our original expectations. There is good business visibility in the short to medium term anchored by commercial and near-commercial molecules. Our focus on execution discipline, customer satisfaction, and protection of business fundamentals is central to ensuring this phase of growth.” He further added that the company is investing in Peptide Manufacturing and a new R&D Centre to lay the groundwork for future growth.
The company will host an Earnings Call at 17:30 IST on Tuesday, May 12, 2026, to discuss its performance. The transcript of the call will be uploaded on the company's website.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.